Incyte Corporation vs Mongodb Inc — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while Mongodb Inc trades at $432.9 (market cap $35.32B). The key difference: Mongodb Inc is the larger of the two by market cap, and Mongodb Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| INCY | MDB | |
|---|---|---|
Market Cap | $24.54B | $35.32B |
Sector | Health | Technology |
52-Week High | $129.93 | $440.25 |
52-Week Low | $81.61 | $204.37 |
Enterprise Value | $20.04B | $32.93B |
Trailing returns across standard periods
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →